Earlier this year in January, AstraZeneca received regulatory clearance from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute the drug across India. The approval was granted in Form CT-20 by the Drugs Controller General of India, officially allowing the sale of Eculizumab concentrate for infusion 300 mg (10mg/ml).
Soliris is indicated for use in patients suffering from Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (ahus)—both are life-threatening conditions that involve the destruction of blood cells and damage to blood vessels. By targeting complement-mediated thrombotic microangiopathy, the drug helps manage symptoms and prevent further complications.
Eculizumab is a special type of medicine called a monoclonal antibody. It helps treat two rare and serious health problems—PNH and ahus.
PNH causes red blood cells to break down, which can lead to blood clots and damage to organs. ahus affects the way blood clots in the body and can cause kidney failure and other dangerous issues.
This medicine works by blocking a harmful process in the body that causes small blood vessels to get clogged, which is part of what makes both conditions so risky.
Also Read: Electricity bills to rise as SC asks states, UTs to clear ₹1.5 lakh crore dues in four years
Shares of AstraZeneca Pharma India Ltd ended lower on Wednesday by 0.24% at ₹8,834.00 on NSE.
(Edited by : Ajay Vaishnav)
